The global Fabry Disease market garnered revenue around USD XX Billion in 2019 and projected to reach USD XX Billion in 2027, with at a compound annual growth rate of 6.9% throughout the estimate period from 2020 to 2027.
Extensive research and development activities is one of the key factors driving the Fabry disease market. On May 30, 2018, Amicus Therapeutics launched Galafold capsules 123mg for the treatment of patients aged 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation. It is also reported that Galafold is the first and only oral precision medicine for Fabry disease in Japan. Apart from this there are many treatment approaches are under clinical trials for the treatment of Fabry disease. For instance, Pegunigalsidase alfa by Protalix is under phase-3 clinical trial for the treatment of patients affected with Fabry disease.
Various other factors such as technological advancements, developing healthcare infrastructure, and favourable reimbursement and funding policies in developed countries are also expected to propel the growth of the market.
However, the lack of awareness of the disease among physicians in developing or underdeveloped countries, diverse range of symptoms, and other complications can hinder the market growth over the forecast period.
This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.
The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Fabry Disease market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Fabry Disease market growth.
The global Fabry Disease market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.
Major manufacturers analysed under this study comprises:
Amgen Inc., Amicus Therapeutics, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, iBio, Inc., Neuraltus Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., AVROBIO, Inc., Idorsia Pharmaceuticals Ltd, Protalix, Sanofi, Shire, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd and others are some of the key players in the global Fabry disease market.
This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:
Global Fabry Disease Market, by Type:
Type-1
Type-2
Global Fabry Disease Market, by Diagnosis & Treatment:
Diagnosis
o Blood Test
o Urine Test
o Thyroid Test
o Lung Function Test
o Imaging
? Electrocardiogram (EKG)
? Echocardiogram
? Brain MRI
? CT Scan
? Others
o Hearing and Eye Examination
o Others
Treatment
o Enzyme Replacement Therapy
o Gene Therapy
o Pharmaceutical Formulations Containing Agalsidase Alfa
o Analgesics
o Anticonvulsants
o Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
o Others
Global Fabry Disease Market, by End User:
Hospitals & Clinics
Diagnostic Centres
Research & Academic Institutes
Others
Regional Analysis and Forecast
Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:
North America
? U.S.
? Canada
Europe
? Germany
? U.K.
? Italy
? France
? Rest of EU
Asia Pacific
? China
? India
? Japan
? Southeast Asia
? Rest of APAC
Central & South America
? Brazil
? Argentina
? Rest of Central & South America
Middle East and Africa
? UAE
? Saudi Arabia
? Rest of MEA
Request Customization
Get a Sample
Get a Sample
Request Customization